WCLC 2025 - Posters & ePosters-P2.02.27 Osimertinib Increases Expression of HER2 and Combination With T-DXd, a HER2-Directed ADC, Enhances Its Efficacy in PDX Models of EGFR Mutant NSCLC

P2.02.27 Osimertinib Increases Expression of HER2 and Combination With T-DXd, a HER2-Directed ADC, Enhances Its Efficacy in PDX Models of EGFR Mutant NSCLC

Back to course

Asset Subtitle

Nicolas Floch

Meta Tag

Speaker Nicolas Floch

Topic Tumor Biology – Preclinical Biology